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Abstract 
Studies on the structures and binding properties of the glycoproteins, purified from human ovarian cyst fluids, will aid the 
understanding of the carbohydrate alterations occurring during the biosynthesis of blood group antigens and neoplasm formation. These 
glycoproteins can also serve as important biological materials to study blood group A, B, H, Le a, Le b, Le x, Le y, T and Tn determinants, 
precursor type I and II sequences and cold agglutinin I and i epitopes. In this study, the binding property of a cyst glycoprotein from a 
human blood group Le(a +) nonsecretor individual, that contains an unusually high amount (18%) of sialic acid (HOC 350) was 
characterized byquantitative precipitin assay with a panel of lectins exhibiting a broad range of carbohydrate-binding specificities. Native 
HOC 350 reacted well only with three out of nineteen lectins tested. It precipitated about 80% of Ricinus communis (RCA1), 50% of 
Triticum vulgaris (WGA) and 37% of Bauhinia purpurea aba (BPA) agglutinins, respectively. However, its asialo product had 
dramatically enhanced reactivity and reacted well with many I / I I  (Galfl 1 ~ 3/4GcNAc), T (Galfl 1 ~ 3GalNAc) and Tn (GaN1Ac a l 
Ser/Thr) active lectins. It bound best to Jacalin, BPA, and abrin-a and completely precipitated all the lectins added. Asialo-HOC 350 
also reacted strongly with Wistaria floribunda, Abrus precatorius aggludnin, ricin and RCA l and precipitated over 75% of the lectin 
nitrogen added, and moderately with Arachis hypogaea, Maclura pomifera, WGA, Vicia viosa-B4, Codium fragile tomentosoides and 
Ulex europaeus-II. But native HOC 350 and its asialo product reacted not at all or poorly with Dolichos biflorus, Hel& pomatia, Lotus 
tetra-gonolobus, Ulex europaeus-I, Lens culinaris lectins and Con A. The lectin-glycoform interactions through bioactive sugars were 
confirmed by precipitin inhibition assay. Mapping the precipitation profiles of the interactions have led to the conclusion that HOC 350 
contains a large number of receptors for I / I I ,  T, and Tn active lectins. But in the untreated (or native) substance, most of these 
determinants are masked by sialic acids. 
Keywords: Lectin binding property; Sialoglycoprotein; Ovarian cyst fluid; (Human) 
1. Introduction 
Progress in the elucidation of the structures of the blood 
group A, B, H, Le a, Le b, T, Tn, 1 and i determinants and 
Abbreviations: HOC, human ovarian cyst glycoprotein; GalNAc, 2- 
acetamido-2-deoxy-D-galactopyranose; G l, D-galactopyranose; LFuc, L- 
fucopyranose; GlcNAc, 2-acetamido-2-deoxy-D-glucopyranose; 
NeuAc/Neu5Ac, N-acetylneuraminic acid; QPA, quantitative precipitin 
assay; QPIA, quantitative precipitin-inhibition assay; GP, glycoprotein; 
Abbreviations of lectins and lectin determinants are shown in Table 1. 
* Corresponding author. Fax: +886 3 3286456 (Lab.); +886 3 
3283031 (Coll.). 
1Applied lectins: the lectins that can be used as tools to study 
glycobiology are defined as applied lectins [6,9,28]. 
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precursor type I and I I  sequences has provided a set of 
reagents in the form of blood group and/or  bioactive 
oligosaccharides, glycoproteins and glycoipids. These 
glyco-reagents can be used to determine the specificity of 
combining sites of macromolecules, including antibodies 
and lectins [1-13]. Such well characterized antibodies and 
applied lectins have been used to study the binding proper- 
ties of glycoconjugates and carbohydrate r ceptors on cell 
membranes. 
Pseudomucinous ovarian cyst fluids and meconium con- 
stitute the best sources of bood group substances [1,4]. 
Knowledge of their structures and binding properties will 
aid in studies of the carbohydrate changes during the 
biosynthesis of blood group antigens and neoplasm forma- 
tion. 
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During the past two decades, the lectin binding proper- 
ties of many water soluble blood group active glyco- 
proteins, purified from human ovarian cyst fluids, have 
been well characterized [5,9-13]. Many of them are being 
used as reagents to study the combining sites of lectins [6]. 
The resulting interaction profiles provide important infor- 
mation concerning the binding properties of applied lectins 
[5,6,9]. However, little is known about he structure of cyst 
sialoglycoproteins and the effect of their sialic acid residues 
on lectin-carbohydrate interaction. In this paper, we de- 
scribe the reactivity of a Le a active cyst glycoprotein, that 
contains about 18% sialic acid [14], with a panel of applied 
lectins. Binding was measured by quantitative precipitin 
(QPA) assay and the sugar specific interactions were con- 
firmed by precipitin inhibition assay (QPIA). The results 
revealed that HOC 350 contains cryptic receptors for I / I I  
(Gal/31 ~ 3/4GcNAc), T (Gal/31 ~ 3GalNAc) and Tn 
(GalNAcctl--* Ser/Thr) active lectins. These receptors 
demonstrate high reactivity after removal of sialic acids. 
2. Experimental procedures 
2.1. Sialogycoprotein 
A sialic acid-rich glycoprotein was isolated from human 
ovarian cyst fluid of a Le(a +) nonsecretor individual [14] 
and defined as HOC 350 (Human Ovarian Cyst sample 
#350). For desialylation, 3 mg HOC 350/ml in 0.01 M 
HC1, was hydrolyzed at 80°C for 90 min. and dialyzed at 
4°C against 20 vol. of water for 48 h, with frequent 
changes of water [15]. The nondialyzable material was 
collected, and freeze-dried. 
2.2. Lectins 
Ricinus communis agglutinin (RCA 1) and ricin were 
purchased from Boehringer Mannheim Biochemical, Ger- 
many; Arachis hypogaea (peanut lectin, PNA), A. integri- 
folia (Jacalin), wheat germ agglutinin (WGA), Vicia vil- 
losa-B4 (VVA-B4), B. purpurea alba (BPA), Lotus te- 
tragonolobus (LTL), Ulex europaeus-I (UEL-I), Ulex eu- 
ropaeus-II (UEL-II), Lens culinaris (LCL) and C. ensi- 
formis agglutinins were from Sigma Chemical Co., St. 
Louis, MO, USA. The Maclura pomifera (MPA), Helix 
pomatia (HPA), Dolichos biflorus (DBA) and Wistaria 
floribunda (WFA) lectins were purified by adsorption to 
insoluble polyeucyl hog gastric (A + H) mucin [4,16,17], 
and eluted by melibiose [13], GalNAc [18], GalNAc [19], 
and lactose [20], respectively. Abrus precatorius agglu- 
tinin (APA) as well as abrin-a, given by Drs. L.P. Chow 
and J.Y. Lin, Institute of Biochemistry, College of 
Medicine, National Taiwan University, Taipei, Taiwan, 
were purified from the seeds of Abrus precatorius (jequir- 
ity bean) by Sepharose 4B and DEAE-cellulose column 
chromatographies [21]. Codium fragile subspecies tomen- 
tosoides (CFT) agglutinin, which was isolated from the 
extract of green marine algae, purified by adsorption on 
immobilized GalNAc resin and elution with 0.05 M 
GalNAc [22], was purchased from Sigma Chemical Co., 
St. Louis, MO, USA. 
2.3. Sugar inhibitors 
Gal/31 --* 4GcNAc (II, N-acetyllactosamine), was pur- 
chased from Toronto Research Chemical Inc., Toronto, 
Canada. P-NO2-phenyl-aGalNAc, GlcNAc, Gal/31 
3GalNAc a 1 ~ benzyl were purchased from Sigma Chem- 
ical Co., St. Louis. MO. USA. 
2.4. Lectinochemical ssays 
Quantitative precipitin and precipitin-inhibition assays 
were performed by a microprecipitin technique [23] using 
4.7 to 6.3 /zg of lectin nitrogen (N) for each determination. 
Samples containing the lectin and varying amounts of 
ligand in a total volume of 300/zl saline were incubated at 
37°C for 1 h and then in the cold for 6 days before 
centrifugation to collect the precipitate. Total N in the 
washed precipitates was estimated by the ninhydrin method 
[24]. 
3. Results and discussion 
The sialoglycoprotein (HOC 350) used for this study 
contains 18% sialic acid and has blood group Le(a +) 
activity. This cyst glycoprotein has the highest content of 
sialic acid that we have yet encountered. Mild acid hydroy- 
sis (pH 2.0, 90°C for 80 min) removed about 80% of its 
sialic acid, while almost all of the sialic acid in armadillo 
and ovine salivary glycoproteins (ASG and OSG) can be 
removed by this condition [15,25]. When the rat sublingual 
glycoprotein (RSL) was hydrolyzed under the same condi- 
tion, the percentage of sialic acid released from RSL is 
similar to that of HOC 350, i.e. about 78% of sialic acid 
was removed. This may be due to the carbohydrate moiety 
of HOC 350 and RSL is more complicated than those of 
OSG and ASG. The nature of the 20% sialic acid resistant 
to mild acid hydrolysis remains to be further investigated. 
The quantitative precipitin (QPA) and precipitin inhibi- 
tion assays (QPIA) were chosen for this study as they are 
well established methods and the results of such analyses 
can provide insight into the affinity of glycoprotein lig- 
ands. 
Among the lectins tested by QPA, native HOC 350 
reacted well with three out of nineteen applied lectins. It 
precipitated about 80% of R. communis agglutinin (RCA I) 
(Table 1 and Fig. lh) and approx. 50% of T. vulgaris 
(WGA) and 37% of B. purpurea alba (BPA) (Table 1 and 
Fig. lb,k), but weakly or not at all the other lectins used. 
However, asialo-HOC 350 reacted with many I / I I  
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(Gal/31 --* 3/4GlcNAc),  T (Gal/31 ~ 3GalNAc) and Tn 
(Ga lNAca l  ~ Ser/Thr)  active lectins. Among these 
lectins, it bound best to jacalin, BPA, and abrin-a (Fig. la 
to lc and Table 1#9,#10 and #12) and precipitated com- 
pletely all the lectin added. It took only 4 to 7 /zg of 
glycoprotein to precipitate 50% of 5.3 to 6.3 /xg of lectin 
nitrogen. Asialo-HOC 350 aso reacted strongly with W. 
foribunda, A. precatorius, ricin and RCA 1 and precipitated 
over 83% of each of the lectins tested (Table 1 and Figs. 
ld and le,h and j). It reacted moderately with A. hy- 
pogaea (Fig. If, Table 1), M. pomifera (Fig. lg, Table 1), 
WGA, and V. villosa-B 4 (Fig. li, Table 1), C. fragile 
tomentosoides and U. europaeus-II (Fig. 1, Table 1). Both 
native HOC 350 and its asialo product reacted not at all or 
poorly with D. biflorus, H. pomatia, L. tetragonolobus, U. 
europaeus-I, L. culinaris lectins and concanavalin A (Con 
A) (Table 1). 
Toxic lectins, in general, contain two kinds of polypep- 
tide chains - -  A and B chains. The A chain acts as a 
catalytic or toxic unit, and the B chain contains combining 
sites for specific carbohydrates [26]. Thus, in comparison 
with most of the other lectins (agglutinins), the toxic 
lectins tested possess only one half of the combining sites, 
but still precipitated strongly with asialo-HOC 350 glyco- 
protein (abrin-a and ricin, Table 1 and Fig. la and Fig. le) 
indicating that HOC 350 and its asialo product contain 
highly potent ligands, especially I / I I  determinants inter- 
acting with these two toxic lectins [30,33]. 
In order to prove that the asialo-HOC 350 glyco- 
protein-lectin interaction occurs through lectin determi- 
Native-HOC 0 Asialo-HOC ( in a to k ) 
A 
U~ 
'13 
4~ 
4~ -H 
.,'4 
U 
4.1 
.,4 
Z 
Abrin-a, 5.8 I.tgN 
a 
7 
5 
4 
3 
2 
1 
0 ~ 
0 :~n 4O 
7 
Ricin, 6.0 IsgN 
6 • 
5 
3 
2 
1 
0 20 4O 
7' 
VVL-B4, 6.3 ggN 
6 i 
5 
4 
3 
2 
BPA, 6.3 ttgN 
b 
0 Z0 40 
PNA, 6.0 I~gN 
f 
WFA, S.O5 I, tgN 
i 
/ 
0 20 4O 
Jacalin, 5.25 I~gN APA, 53 I~gN 
c d 
F 
~ . | . | 
0 20 4O 0 20 4O 
MPL, 5.7 rtgN 
8 
/ 
0 20 4O 
WGA, 5.0 I~gN 
k 
• N 
0 20 40 
C~,  4.7 ~gN • 
I LTL, 5.3 I~gN • 
UEL-II, 5.5 I~gN& 
A~ialoform 
OUIA  
0 ~ 40 0 20 40 
Glycoprote in  added (~g)  
Fig. 1. Quantitative precipitation curves of HOC 350 and asialo-HOC 350 active glycoproteins from human ovarian cyst fluid with Ga and GalNAc 
specific lectins. The amount of lectin nitrogen added ranged from 4.9-6.3 /xg, as listed in Table 1. Total volume: 300 I~l. D. biflorus, H. pomatia, L. 
tetrago nolobus, U. europaeus-l, L. culinaris and C. ensiformis were inactive, 
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nants rather than being nonspecific, the Tn, T and I I  
determinants (p -n i t ropheny l -a -DGalNAc;  Gal/3 1 
3GalNAcc~l- -*  OCH 2 .phenyl ,  T , ;  and Gal/31 
4GlcNAc, II), and GlcNAc were used to inhibit the 
lectin-asialo-HOC 350 glycoprotein association. When the 
inhibition assay was performed in the range from 4.7/xg to 
5.8 /xg of lectin nitrogen (abrin-a, APA, WFA, Jacain and 
BPA) and 5 /~g sialoglycoprotein reaction (Table 2), 81 to 
97% of the precipitation was inhibited by 0.2 /zmol and 
1.0 /zmol of Gal/31 ~ 3Ga lNAca l  ~ OCH2.phenyl(T ~) 
and Gal/3 1 -~ 4GlcNAc (II), respectively, but not at all or 
insignificantly by 11.5 /.tmol of GIcNAc. 
Mapping the interaction profiles (Table 1) of the results 
obtained from QPA and QPIA, it can be concluded that 
HOC 350 contains cryptic receptors for I / I I ,  T, and Tn 
active lectins. But in the untreated (or native) substance, 
most of the reactive structures are shielded by sialic acid. 
During neoplastic transformation, the carbohydrate 
chains including blood-group antigens in glycolipids and 
glycoproteins are frequently altered [34,35]. T and Tn 
determinants have been detected in various human carcino- 
mas and correlated with carcinoma ggressiveness [36-40]. 
Sialic acid also plays a role in tumor cell metastasis [41]. It 
has been reported to be a high sensitive tumor marker in a 
variety of cancerous conditions. Therefore, using applied 
lectins to study the binding properties of cyst sialglycopro- 
tein will help us to understand the carbohydrate changes 
during normal and pathological processes in living organ- 
isms. 
During the past four decades, the chemical structures of 
the blood group A, B, H, Le a, Le b, Le x and Le y determi- 
nants in water soluble blood group substances of human 
ovarian cyst fluid have been established (reviewed in 
[5,8]). The human blood group A, B, H, Le a, Le b, Le x and 
Le y active oligosaccharides purified from human ovarian 
cyst fluid have been combined in the structure below 
[5,8,421. 
"tZ ZZZ 
[~] [3 ]  
[ ?1~ c~d-~ ~[91 
[81- , .G~ Glc~c' - [  10 l 
~1, 6 ~i, 6 
I [ l]~Gal~l--b3G~l~3Ga~l~3Gl~1~3Gal~l~3GaiNAcal~Ser or Thr 
The above structure shows the proposed representative 
carbohydrate side chains of blood group active glyco- 
proteins, prepared from human ovarian cyst fluid. The 
four-branched structure (I to IV) shown is the representa- 
tive internal portion of the carbohydrate moiety of blood 
group substances to which the residues responsibe for A, 
B, H, Le a, and Le b activities are attached. This structure 
represents precursor blood group active glycoproteins 
[5,6,8,11,42]. The numbers in parentheses [1] to [12] indi- 
cate the site of attachment of sugars that complete the 
determinants, in which [1] to [4] can be GalNAc c~ l ~ 3 
for blood group A active sites; or Ga a 1 ~ 3 for B active 
sites; [5], [7], [9] and/or  [11] are LFuca l  ~ 2 for H 
active sites; [6] is LFuc a 1 --* 4 for Le a active site and [8], 
[10] and/or  [12] is LFuca 1 ~ 3 for Le x active site. These 
determinants a well as the structural units at the nonreduc- 
ing end are the sources of lectin A /A  h, B, I / I I ,  T, and 
Tn determinants [6,9,28]. A megalo-saccharide of 24 sug- 
ars has not been isolated. However, most of the carbo- 
hydrate chains isolated are parts of this structure including 
short chains of T and Tn determinants [5,8]. The complete 
composite structure is considered to be the core structure 
with four branches to which the key sugar of the blood 
Table 2 
Inhibition of Asialo-HOC 350 glycoprotein-Lectin Interaction by p-nitrophenyl-a-D-GalNAc, Gal fl 1 ~ 4GlcNAc(II), Gal fl I ~ 3GalNAc ot I ~ OCH 2 . 
phenyl(T,) and GIcNAc a 
Lectin tested Amount of Inhibition (%) b 
lectin (/xgN) 1.2 /zmol 1.0/zmol Gal fl 1 ~ 0.2 /zmol Gal/31 ~ 11.5/zmol 
p-nitrophenyl-ot-DGalNAc 4GIcNAc added 3GalNAc o~ 1 ~ GIcNAc added 
added OCH 2 • phenyl added 
Abrin-a 5.8 32.0 94.0 81.2 8.5 
A. precatorius (APA) 5.5 42.8 97.1 96.5 1.7 
W. floribunda (WFA) 5.1 97.9 96.0 18.9 0 
A. integrifolia (Jacalin) 5.8 100.0 0 97.6 11.4 
B. purpurea lba (BPA) 4.7 90.1 73.0 90.8 20.1 
A range from 4.7 to 5.8 FgN of lectins in 3.0 ml glass centrifuge tube was mixed with or without (control) 1.2 /zmol p-nitrophenyl-ct-DGalNAc, 1.0 
/xmol Galfl 1 ~ 4GlcNAc, 0.2 /~mol Gal fl 1 ~ 3GalNAc a 1 ~ OCH 2 • phenyl and 11.5/xmol GlcNAc, separately, asinhibitors. After incubation at37°C 
for 30 min, 5 /xg of asialo-HOC 350 glycoprotein was added, and subsequently incubated at the same temperature for 1 h and at 4°C for 6 days. 
b % of inhibition = difference between A570 of nitrogen content in the precipitate without and with inhibitor added/As70 of nitrogen content in the 
precipitate without inhibitor added × 100. 
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group A, B, H, Le a, Le b, Le x and Le y determinants may 
be attached at the appropriate location along the branches. 
However, although this composite structure was con- 
structed from the characterized fragments isolated from 
ovarian cyst glycoproteins, a complex structure bearing all 
these units on single oligosaccharide chain has not yet 
been isolated, and most of the chains are known to be 
shorter and less branched [5,8]. The structures of the 
carbohydrate chains in the sialoglycoprotein (HOC 350) 
used in this investigation have not been established, but as 
it is an Le a active substance, the A, B, H, Le b and Le y 
determinants are absent and only the fucosylated Le a and 
Le x determinants, and the sialylated precursor structures, 
would be expected to be present as terminal sequences in
the unhydrolyzed material. 
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